Express Scripts reaches ‘landmark’ settlement with FTC in insulin suit

The agreement announced Wednesday includes sweeping changes to the Cigna PBM’s business practices, including no longer preferring expensive drugs over cheaper equivalents on standard formularies and reshoring its controversial rebate aggregator.

By Rebecca Pifer Parduhn • Updated Feb. 4, 2026

Trump signs funding bill with PBM reforms, hospital-at-home and telehealth extensions

The funding package ends a partial government shutdown and enacts several healthcare policies, including preserving telehealth flexibilities in Medicare through 2027.

By Emily Olsen • Feb. 4, 2026

Explore the Trendline➔

Commercialization

New drugs for obesity are becoming blockbusters, while Trump administration pressure is reshaping pharma marketing strategies ahead of looming patent cliffs.

By BioPharma Dive staff

Novo shares tumble by double digits on grim sales outlook

In contrast to Lilly’s optimistic forecasts, Novo cited pricing constraints and competitive pressure in predicting up to a 13% decline in 2026 profits. 

By Jonathan Gardner • Feb. 4, 2026

Lilly soars again as fast-selling weight loss drugs top Wall Street projections

Despite some angst over pricing pressure for GLP-1 drugs, Lilly’s bullish projections surpassed consensus estimates, while combined 2025 sales of Zepbound and Mounjaro eclipsed $36 billion.

By Kristin Jensen • Feb. 4, 2026

Earnings roundup: Amgen vs. FDA, Pfizer’s defense and Merck’s $70B-in-sales plan

Amgen is refusing U.S. regulators’ request to withdraw an inflammatory disease drug. Elsewhere, Pfizer battled skepticism on new obesity drug data, and Merck laid out its post-Keytruda future.

By BioPharma Dive staff • Feb. 4, 2026

Drugs for cancer, arthritis and HIV on Medicare’s list for 2028 price cuts

Still, the medications in the latest round of negotiations — which now includes “Part B” drugs given in doctors offices — draw very limited revenue from Medicare, an analyst pointed out.

By Jonathan Gardner • Jan. 28, 2026

Lilly, chasing Novo, expects second-quarter FDA decision on obesity pill

Speaking at the J.P. Morgan conference, CEO David Ricks said he anticipates a “rapid review” for orforglipron that's currently speeding along “at pace.” 

By Jonathan Gardner • Jan. 14, 2026

Building more sustainable cold chain packaging through innovation

Working towards the future of cold chain packaging: sustainable packaging without performance tradeoffs.

By Cryopak • Jan. 12, 2026

Argenx falters in effort to expand immune drug’s use

The company will stop two trials testing its blockbuster therapy Vyvgart in thyroid eye disease after treatment was judged to be ineffective at an interim checkpoint.

By Jonathan Gardner • Dec. 15, 2025

Crapo, Cassidy propose enhanced ACA subsidy alternative

The legislation, which is scheduled for a vote Thursday, would send funds directly to health savings accounts paired with bronze or catastrophic plans offered on the Affordable Care Act exchanges.

By Emily Olsen • Dec. 11, 2025

J&J’s ‘remarkable’ Tecvayli data support earlier use in multiple myeloma

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have curative potential early in a patient’s disease course.

By Jonathan Gardner • Dec. 9, 2025

At ASH, Lilly makes case to widen Jaypirca use in leukemia, lymphoma

In a head-to-head trial, Lilly’s drug was as effective as Imbruvica at inducing responses and displayed certain safety advantages that could make it a preferred treatment in early lines of care. 

By Jonathan Gardner • Dec. 7, 2025

RFK Jr.’s hand-picked panel questions childhood vaccine schedule

After weakening an endorsement for the hepatitis B vaccine, ACIP began debating the merits of the protocol used to inoculate U.S. children against many infectious diseases.

By Delilah Alvarado • Dec. 5, 2025

Hemophilia gene therapies are struggling on the market, even as innovation soars

The business case for hemophilia gene therapy still isn’t adding up due to persistent market barriers.

By Kelly Bilodeau • Dec. 5, 2025

CMS sets 2027 Medicare prices for Wegovy, Trelegy and 13 other drugs

The second round of negotiations cuts spending an aggregate 44% over 2024 list prices as the federal government extends restraints over more medicines.

By Jonathan Gardner • Nov. 26, 2025

GSK, Anaptysbio sue each other over Jemperli revenue

As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding development of the cancer immunotherapy.

By Jonathan Gardner • Nov. 21, 2025

With new approvals, Regeneron’s higher-dose Eylea gets more competitive

Analysts say the two new indications should help Eylea HD as Regeneron battles for market share with Roche’s Vabysmo.

By Kristin Jensen • Nov. 20, 2025

Agios shares fall on mixed sickle cell results for blood disease drug

Pyrukynd, which Agios sells for a rare type of anemia, missed one of its main objectives in a study seen as crucial for its commercial outlook and the company’s reinvention as a rare disease specialist.

By Jonathan Gardner • Nov. 19, 2025

Novo, Lilly cut deal with Trump to lower prices of obesity drugs

The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.

By Jonathan Gardner • Updated Nov. 7, 2025

Vertex’s new pain, blood disorder drugs miss Wall Street expectations

While the launches of Journavx and Casgevy have started to build steam, “investors may not be inclined to look past the clear revenue misses,” wrote a Raymond James analyst.

By Jacob Bell • Nov. 4, 2025

4 must-have capabilities in a digital health partner in the era of AI

Unlock the 4 must-have traits that make digital health partners game-changers in pharma.

Nov. 3, 2025

FDA, aiming to lower drug costs, moves to speed approval of biosimilars

The agency will no longer require studies comparing copycat biologics to their branded counterparts, which could help developers bring them to market more quickly and cheaply. 

By Jonathan Gardner • Oct. 29, 2025

Lilly aligns with Walmart in bid to broaden access to discounted Zepbound

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest move by the company to expand its direct-to-consumer services. 

By Jonathan Gardner • Oct. 29, 2025

Iambic partners with Jazz; Merck breaks ground on $3B plant

The biotechs will assess a combination of two drugs against HER2-positive breast cancer. Elsewhere, Merck unveiled the latest piece of its more than $70 billion domestic manufacturing investment.

By BioPharma Dive staff • Oct. 21, 2025

Novo’s main shareholder pushes out more than half of company’s board

The Novo Foundation chair said the current board of the Wegovy maker, which is already dealing with layoffs and a CEO change, was too slow to react to obesity market shifts.

By Jonathan Gardner • Oct. 21, 2025